Alzheimer’s disease hypothesis and related therapies

Oxidative stress and the amyloid beta peptide in Alzheimer’s disease

(2018) C. Cheignon et al.   Redox Biology

The Vagus Nerve in Appetite Regulation, Mood, and Intestinal Inflammation

(2017) Kirsteen N. Browning et al.   GASTROENTEROLOGY

Regionalized Development and Maintenance of the Intestinal Adaptive Immune Landscape

(2017) William W. Agace et al.   IMMUNITY

Homeostatic Immunity and the Microbiota

(2017) Yasmine Belkaid et al.   IMMUNITY

Cholinergic modulation of the hippocampal region and memory function

(2017) Juhee Haam et al.   JOURNAL OF NEUROCHEMISTRY

Inhibition of AGEs/RAGE/Rho/ROCK pathway suppresses non-specific neuroinflammation by regulating BV2 microglial M1/M2 polarization through the NF-κB pathway

(2017) Jingkao Chen et al.   JOURNAL OF NEUROIMMUNOLOGY

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

(2017) Petr Novak et al.   LANCET NEUROLOGY

Solanezumab: too late in mild Alzheimer's disease?

(2017) The Lancet Neurology   LANCET NEUROLOGY

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2017) Jeff Sevigny et al.   NATURE

Microglia emerge as central players in brain disease

(2017) Michael W Salter et al.   NATURE MEDICINE

Tau-based therapies in neurodegeneration: opportunities and challenges

(2017) Chuanzhou Li et al.   NATURE REVIEWS DRUG DISCOVERY

A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain

(2017) Jun Wang et al.   Nature Reviews Neurology

Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly

(2017) Annamaria Cattaneo et al.   NEUROBIOLOGY OF AGING

Microglia Responses in Acute and Chronic Neurological Diseases: What Microglia-Specific Transcriptomic Studies Taught (and did Not Teach) Us

(2017) Hélène E. Hirbec et al.   Frontiers in Aging Neuroscience

PD1 Negative and PD1 Positive CD4+ T Regulatory Cells in Mild Cognitive Impairment and Alzheimer's Disease

(2017) Marina Saresella et al.   JOURNAL OF ALZHEIMERS DISEASE

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

(2016) Eric R. Siemers et al.   Alzheimers & Dementia

Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation

(2016) Hansen Lui et al.   CELL

New insights on the role of microglia in synaptic pruning in health and disease

(2016) Soyon Hong et al.   CURRENT OPINION IN NEUROBIOLOGY

Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs?

(2016) Feng Chen et al.   JOURNAL OF ETHNOPHARMACOLOGY

Cerebral hypoperfusion and glucose hypometabolism: Key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease

(2016) Mak Adam Daulatzai   JOURNAL OF NEUROSCIENCE RESEARCH

Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial

(2016) Serge Gauthier et al.   LANCET

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease

(2016) Kuti Baruch et al.   NATURE MEDICINE

TREM2 variants: new keys to decipher Alzheimer disease pathogenesis

(2016) Marco Colonna et al.   NATURE REVIEWS NEUROSCIENCE

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease

(2016) Matthew R. Brier et al.   Science Translational Medicine

Drug development in Alzheimer’s disease: the path to 2025

(2016) Jeffrey Cummings et al.   Alzheimers Research & Therapy

Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin

(2016) Mark Ultsch et al.   Scientific Reports

Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models

(2015) Yvonne Bouter et al.   ACTA NEUROPATHOLOGICA

Serotonin, tryptophan metabolism and the brain-gut-microbiome axis

(2015) S.M. O’Mahony et al.   BEHAVIOURAL BRAIN RESEARCH

The blood-brain barrier in neuroimmunology: Tales of separation and assimilation

(2015) W.A. Banks   BRAIN BEHAVIOR AND IMMUNITY

Control of Brain Development, Function, and Behavior by the Microbiome

(2015) Timothy R. Sampson et al.   Cell Host & Microbe

Microbiota and host immune responses: a love-hate relationship

(2015) Sarah Tomkovich et al.   IMMUNOLOGY

Host microbiota constantly control maturation and function of microglia in the CNS

(2015) Daniel Erny et al.   NATURE NEUROSCIENCE

Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

(2015) Erik S Musiek et al.   NATURE NEUROSCIENCE

Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice

(2015) Meaghan Morris et al.   NATURE NEUROSCIENCE

Solanezumab—prospects for meaningful interventions in AD?

(2015) Sam Gandy et al.   Nature Reviews Neurology

Thinking outside the brain for cognitive improvement: Is peripheral immunomodulation on the way?

(2015) Xiao Zheng et al.   NEUROPHARMACOLOGY

Role of the Microbiota in Immunity and Inflammation

(2014) Yasmine Belkaid et al.   CELL

Targeting microglia for the treatment of Alzheimer’s disease

(2014) Patrick L McGeer et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Vagus nerve controls resolution and pro-resolving mediators of inflammation

(2014) Valbona Mirakaj et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Targeting the Prodromal Stage of Alzheimer’s Disease: Bioenergetic and Mitochondrial Opportunities

(2014) Charles C. Caldwell et al.   Neurotherapeutics

Oxidative Stress in Alzheimer’s Disease: Why Did Antioxidant Therapy Fail?

(2014) Torbjörn Persson et al.   Oxidative Medicine and Cellular Longevity

The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism

(2014) Gary Frost et al.   Nature Communications

Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease

(2013) Bin Zhang et al.   CELL

Safety and Pharmacology of Ponezumab (PF-04360365) After a Single 10-Minute Intravenous Infusion in Subjects With Mild to Moderate Alzheimer Disease

(2013) Aaron H. Burstein et al.   CLINICAL NEUROPHARMACOLOGY

Safety and Pharmacology of a Single Intravenous Dose of Ponezumab in Subjects With Mild-to-Moderate Alzheimer Disease

(2013) Jaren W. Landen et al.   CLINICAL NEUROPHARMACOLOGY

Alzheimer’s Disease and Antioxidant Therapy: How Long How Far?

(2013) J. Teixeira et al.   CURRENT MEDICINAL CHEMISTRY

Microbial amyloids – functions and interactions within the host

(2013) Kelly Schwartz et al.   CURRENT OPINION IN MICROBIOLOGY

Synaptic plasticity in health and disease: introduction and overview

(2013) T. V. P. Bliss et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

An Overview of PET Neuroimaging

(2013) Ilya Nasrallah et al.   SEMINARS IN NUCLEAR MEDICINE

Alzheimer's disease and the microbiome

(2013) Surjyadipta Bhattacharjee et al.   Frontiers in Cellular Neuroscience

The Complement System: An Unexpected Role in Synaptic Pruning During Development and Disease

(2012) Alexander H. Stephan et al.   Annual Review of Neuroscience

The interplay between the intestinal microbiota and the brain

(2012) Stephen M. Collins et al.   NATURE REVIEWS MICROBIOLOGY

Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour

(2012) John F. Cryan et al.   NATURE REVIEWS NEUROSCIENCE

Neuroinflammation: A Common Pathway in CNS Diseases as Mediated at the Blood-Brain Barrier

(2012) Michelle A. Erickson et al.   NEUROIMMUNOMODULATION

TREM2 Variants in Alzheimer's Disease

(2012) Rita Guerreiro et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Human Gut Microbiota and Undernutrition

(2012) J. I. Gordon et al.   Science Translational Medicine

Major histocompatibility complex class I proteins in brain development and plasticity

(2012) Bradford M. Elmer et al.   TRENDS IN NEUROSCIENCES

Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease

(2011) Qin Nie et al.   ACTA PHARMACOLOGICA SINICA

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)

(2011) Paul S. Aisen et al.   Archives of Medical Science

Structural Basis of C-terminal β-Amyloid Peptide Binding by the Antibody Ponezumab for the Treatment of Alzheimer's Disease

(2011) Sherry L. La Porte et al.   JOURNAL OF MOLECULAR BIOLOGY

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

(2011) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer's disease

(2011) Marina Saresella et al.   NEUROBIOLOGY OF AGING

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

(2011) S. Salloway et al.   NEUROLOGY

Synaptic Pruning by Microglia Is Necessary for Normal Brain Development

(2011) R. C. Paolicelli et al.   SCIENCE

Modulation of Brain Dead Induced Inflammation by Vagus Nerve Stimulation

(2010) S. Hoeger et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions

(2010) David W. Klaver et al.   BIOLOGICAL CHEMISTRY

A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE

(2010) D. T. Laskowitz et al.   NEUROLOGY

Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria

(2009) Ivaylo I. Ivanov et al.   CELL

Exploring the link between inflammation and the vagus nerve

(2009) J.-J. De Haan et al.   JOURNAL OF INTERNAL MEDICINE

Amyloid-β as a positive endogenous regulator of release probability at hippocampal synapses

(2009) Efrat Abramov et al.   NATURE NEUROSCIENCE

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Cytokines and CNS Development

(2009) Benjamin E. Deverman et al.   NEURON

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET

Redox proteomics studies ofin vivo amyloid beta-peptide animal models of Alzheimer's disease: Insight into the role of oxidative stress

(2008) Rukhsana Sultana et al.   Proteomics Clinical Applications